CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™

Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile
Provides timely clinical protection for adults aged 18 and above, including those over 60
TIANJIN, China, May 24, 2021 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™), has been granted a Good Manufacturing Practice ("GMP") certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021 after a thorough inspection of CanSinoBIO's production of Convidecia™.
The GMP certificate recognizes that CanSinoBIO's manufacturing facilities and quality control system comply with the high production standards and guidelines required by the European Union ("EU"). The EU GMP certification is required to import COVID-19 vaccines into the European Union and is regarded as a recognition of leading industry standards by many authorities outside of the EU. This certification signifies CanSinoBIO's readiness to enter more markets in Europe and globally.

Related Keywords

Mexico ,Shanghai ,China ,Xuefeng ,Hunan ,Tianjin ,Hungary ,Chile ,Pakistan ,Hungarian , ,Prnewswire Cansino Biologics Inc ,European Union ,National Medical Products Administration Of China ,Hungarian National Institute Of Pharmacy ,Shanghai Pharmaceuticals Holding Co Ltd ,Sino Biologics ,Recombinant Novel Coronavirus Vaccine ,Adenovirus Type ,Good Manufacturing Practice ,Hungarian National Institute ,Chief Executive Officer ,National Medical Products Administration ,Cansino Biologics Inc ,மெக்ஸிகோ ,ஷாங்காய் ,சீனா ,ஹுனன் ,பசி ,சிலி ,பாக்கிஸ்தான் ,ஐரோப்பிய தொழிற்சங்கம் ,பசி தேசிய நிறுவனம் ஆஃப் மருந்தகம் ,ஷாங்காய் மருந்துகள் வைத்திருத்தல் இணை லிமிடெட் ,சினோ உயிரியல் ,நல்ல உற்பத்தி ப்ர்யாக்டீஸ் ,பசி தேசிய நிறுவனம் ,தலைமை நிர்வாகி அதிகாரி ,கேன்சினோ உயிரியல் இன்க் ,